PAINCHEK LTD — Capital/Financing Update 2017

Sep 7, 2017

Improving the quality of life for people in pain through novel, cost effective pain assessment tools

ASX Release 8[th] September 2017

ePAT Technologies Limited ABN 21 146 035 127 Suite 401, 35 Lime Street, Sydney, NSW, 2000 Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008 Phone +61 8 9388 8290

Allotment of Deferred Consideration Shares

As announced at ASX on 19[th] July 2017, the ePAT pain assessment App has been CE marked and is included on the TGA Australian Register of Therapeutic Goods (ARTG) as a Class 1 medical device.

Achievement of regulatory approval triggered ePAT vendors’ entitlement to deferred consideration shares to the value of $1,000,000 AUD calculated at a 5 day VWAP prior to achieving the milestone, which has been calculated at 2.6 cents – resulting in 38,461,538 ePAT shares to be issued. See terms in the Prospectus dated 25 August 2016. These shares are to be escrowed for the balance of the 24 months from the date of official quotation of the Company’s securities (19 October 2018).

The appropriate restriction agreements have now been executed and the deferred consideration shares allotted. The Appendix 3B follows.

==> picture [81 x 25] intentionally omitted <==

Ian Hobson Company Secretary

PO Box 226, Subiaco WA 6904 | Email: ianhobson@bigpond.com | www.epattechnologies.com

About ePAT:

ePAT Technologies Limited is an Australian based company which is developing mobile medical applications that are intended to provide pain assessment for individuals that are unable to communicate verbally with their carers.

The ePAT business:

The ePAT business has evolved from research undertaken by Curtin University in Western Australia over the past 3 years. ePAT now owns the intellectual property resulting from Curtin University’s research on the ePAT Apps.

ePAT’s technology, a mobile application ( ePAT App ), uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro- expressions that are indicative of the presence of pain. This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured through the ePAT App to calculate a pain severity score.

Due to its ease of use and its reproducibility, it is intended that the ePAT App will be able to be used in the first instance to detect and measure a person’s pain, and then further measurements can be used to monitor the effectiveness of pain management provided to the person. The ePAT App is being developed and will be rolled out globally in two phases: first, the ePAT App for Dementia for persons who have lost the ability to communicate with their carers, and the second, the ePAT App for Children who have not yet learnt to speak.

For further information, please contact:

Ian Hobson Philip Daffas Company Secretary Managing Director Tel: +61 8 9388 8290 Tel: +61 406-537-235